A New 675 nm Laser Device in the Treatment of Melasma: Results of a Prospective Observational Study

Nisticò, Steven Paul; Tolone, Martina; Zingoni, Tiziano; Tamburi, Federica; Scali, Elisabetta; Bennardo, Luigi; Cannarozzo, Giovanni

doi:10.1089/photob.2020.4850

Cited by 40 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commercial skin whiteners, such as kojic acid (KA), hydroquinone (HQ) and arbutin (glycosylated HQ) are known to exhibit serious side effects [ 31 , 32 ], prompting a need for safer and nontoxic alternatives for the treatment of hyperpigmentation disorders of the skin [ 33 ]. Curcumin, a polyphenolic bioactive compound, isolated from the rhizomes of turmeric, Curcuma longa , is a popular nutraceutical compound with a broad spectrum of pleiotropic activities that is used as an oral supplement in the management of various cutaneous conditions [ 34 ] and is reported to inhibit cellular melanogenesis [ 35 , 36 , 37 , 38 , 39 ].…”

Section: Introductionmentioning

confidence: 99%

Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

Goenka

Simon

2021

IJMS

View full text Add to dashboard Cite

Hyperpigmentation is a dermatological condition characterized by the overaccumulation and/or oversecretion of melanin pigment. The efficacy of curcumin as an anti-melanogenic therapeutic has been recognized, but the poor stability and solubility that have limited its use have inspired the synthesis of novel curcumin analogs. We have previously reported on comparisons of the anti-melanogenic activity of four novel chemically modified curcumin (CMC) analogs, CMC2.14, CMC2.5, CMC2.23 and CMC2.24, with that of parent curcumin (PC), using a B16F10 mouse melanoma cell model, and we have investigated mechanisms of inhibition. In the current study, we have extended our findings using normal human melanocytes from a darkly pigmented donor (HEMn-DP) and we have begun to study aspects of melanosome export to human keratinocytes. Our results showed that all the CMCs downregulated the protein levels of melanogenic paracrine mediators, endothelin-1 (ET-1) and adrenomedullin (ADM) in HaCaT cells and suppressed the phagocytosis of FluoSphere beads that are considered to be melanosome mimics. All the three CMCs were similarly potent (except CMC2.14, which was highly cytotoxic) in inhibiting melanin production; furthermore, they suppressed dendricity in HEMn-DP cells. CMC2.24 and CMC2.23 robustly suppressed cellular tyrosinase activity but did not alter tyrosinase protein levels, while CMC2.5 did not suppress tyrosinase activity but significantly downregulated tyrosinase protein levels, indicative of a distinctive mode of action for the two structurally related CMCs. Moreover, HEMn-DP cells treated with CMC2.24 or CMC2.23 partially recovered their suppressed tyrosinase activity after cessation of the treatment. All the three CMCs were nontoxic to human dermal fibroblasts while PC was highly cytotoxic. Our results provide a proof-of-principle for the novel use of the CMCs for skin depigmentation, since at low concentrations, ranging from 5 to 25 µM, the CMCs (CMC2.24, CMC2.23 and CMC2.5) were more potent anti-melanogenic agents than PC and tetrahydrocurcumin (THC), both of which were ineffective at melanogenesis at similar doses, as tested in HEMn-DP cells (with PC being highly toxic in dermal fibroblasts and keratinocytes). Further studies to evaluate the efficacy of CMCs in human skin tissue and in vivo studies are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

Goenka

Simon

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Most whitening agents may be classified based on their different mechanisms of action, including the interference with melanin synthesis and transport and the acceleration of melanin decomposition [27]. Additionally, using a novel 675 nm laser may be considered promising when treating benign pigmented lesions, due to a low risk of side effects and simple post-treatment management [28].…”

Section: Discussionmentioning

confidence: 99%

Inhibitory Effect and Mechanism of Scutellarein on Melanogenesis

Dai

Maeda

2021

Cosmetics

View full text Add to dashboard Cite

Fairer skin is preferred in many Asian countries and there is a high demand for skin whitening and lightening products. However, in recent years, problems related to the safety of using whitening agents have emerged. This study demonstrates that plant-derived scutellarein effectively inhibits melanogenesis in B16 melanoma cells. However, baicalein, which is similar to scutellarein in its chemical structure, does not show any inhibitory effect on melanogenesis. Cellular tyrosinase activity is decreased by scutellarein in a dose-dependent manner. No cytotoxicity is observed at the effective concentration range. Additionally, both the protein and mRNA levels of tyrosinase are significantly decreased by scutellarein. Further, the risk of leukoderma development also is determined by evaluating the production of free hydroxyl radicals (˙OH); scutellarein treatment does not induce ˙OH production. Scutellarein shows no risk of causing leukoderma. Our results suggest that scutellarein or plant extracts containing high concentrations of scutellarein have the potential to inhibit melanin production and serve as cosmetic skin-lightening agents.

show abstract

“…Tranexamic acid, a plasmin inhibitor, has been used as an anticoagulant in the past but is now used as a melasma-whitening agent [20]. Chemical peels in combination with other drugs are used for limited forms, and oral tranexamic acid may be used in the treatment of refractory melasma after screening for thromboembolism [21]. In a previous study, tranexamic acid was found to inhibit plasminogen binding to keratinocytes, preventing UV-induced pigmentation and reducing the tyrosinase activity of melanocytes.…”

Section: Examples Of Drug Repositioning In Dermatologymentioning

confidence: 99%

Development of Pigmentation-Regulating Agents by Drug Repositioning

Jeong

Yoon

2021

IJMS

View full text Add to dashboard Cite

Skin color is determined by the processes of melanin synthesis and distribution. Problems in various molecules or signaling pathways involved in melanin synthesis contribute to skin pigmentation defects. Several trials have been conducted on the production of pigmentation-regulating agents, and drug repositioning has emerged as a modern technique to identify new uses for existing drugs. Our research team has researched substances or drugs associated with pigmentation control and, as a result, nilotinib, sorafenib, and ICG-001 have been found to promote pigmentation, while 5-iodotubercidin inhibits pigmentation. Therefore, these substances or medications were suggested as potential therapeutics for pigmentation disorders by drug repositioning.

show abstract

A New 675 nm Laser Device in the Treatment of Melasma: Results of a Prospective Observational Study

Cited by 40 publications

References 12 publications

Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

Inhibitory Effect and Mechanism of Scutellarein on Melanogenesis

Development of Pigmentation-Regulating Agents by Drug Repositioning

Contact Info

Product

Resources

About